Who is sponsoring NCT05895448?

NCT05895448 is sponsored by Center For Hepatitis C, Atlanta, GA.

What drugs are being tested in NCT05895448?

Interventions in NCT05895448: velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) ..

What condition does NCT05895448 study?

NCT05895448 studies Chronic Hepatitis C, People Who Inject Drugs.

Is NCT05895448 still recruiting?

NCT05895448 is currently status unknown. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT05895448

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics

Status unknown Phase 4 Last updated 8 June 2023

What this trial tests

Phase 4 trial testing velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) . in Chronic Hepatitis C in 125 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 November 2023

1 January 2024

Quick facts

Lead sponsor	Center For Hepatitis C, Atlanta, GA
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	125
Start date	1 March 2018
Primary completion	1 November 2023
Estimated completion	1 January 2024
Sites	1 location across United States

Drugs / interventions tested

velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) . — full drug profile →

Conditions studied

Chronic Hepatitis C — all drugs for Chronic Hepatitis C →
People Who Inject Drugs — all drugs for People Who Inject Drugs →

Sponsor

Center For Hepatitis C, Atlanta, GA — full company profile →

Who can join

Adults 18 to 75, any sex, with Chronic Hepatitis C or People Who Inject Drugs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Direct antiviral therapy (standard of care) administered to chronic hepatitis C-infected patients, in two hepatology clinics, who had used intravenous drugs in the past 6 months of signing informed consent (IC). This cohort was compared to concurrently treated chronic hepatitis C patients who were not intravenous drug users, who signed IC in these same clinics. Follow-up expected two years after cure and relapse rates recorded. Primary end point was SVR rate and secondary end points included reinfection rates in follow-up period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Hepatitis C

Currently open trials in the same condition.

NCT06180590 — The Efficacy of Vosevi in Treating DAA-experienced Patients · recruiting
NCT03993925 — Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05895448 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center For Hepatitis C, Atlanta, GA
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05895448.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing